Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase NA 10Phase 1 9Phase 3 6Phase 4 5Phase 1/2 4Phase 2/3 1

Status

Completed 6Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Completed × Folic Acid × Clear all
NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 3 Completed
324 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02578680 2024-09-20

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
616 enrolled 19 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03950674 2024-06-10

MK-3475-189

Merck Sharp & Dohme LLC

Phase 3 Completed
40 enrolled 20 charts
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03349333 2019-10-01

A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL

Mundipharma (China) Pharmaceutical Co. Ltd

Phase 3 Completed
85 enrolled 26 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT00806819 2017-02-02

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Boehringer Ingelheim

Phase 3 Completed
718 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00973609 2015-09-01

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)

AIO-Studien-gGmbH

Phase 3 Completed
853 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡